Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjoncology logo
VJHemOnc
Logo
  • Home (current)
  • Diseases
    CLL
    Multiple Myeloma
    Myeloproliferative Neoplasms
    ALL
    AML
    Lymphoma
    View all Diseases
  • Topics
    Transplantation
    Measurable Residual Disease
    CAR-T & Cellular Therapy
    Pharmacy
    Nursing
    Supportive Care
    View all Topics
  • Conferences
    ASH
    2019
    MPN Advances Day
    2019
    iwCAR-T
    2019
    COSTEM
    2019
    ESMO
    2019
    iwCLL
    2019
    View all Conferences
  • Features
  • Podcasts
    • About
    • Board
    • News
    • Sign Up
    • Contact

ASCO 2019 | Patient-reported outcomes with CAR T-cell therapy

Surbhi Sidana

Surbhi Sidana, MD, of the Mayo Clinic, Rochester, MN, talks about patient-reported outcomes (PROs) for patients undergoing CAR T-cell therapy at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics
  • QoL
  • side effects
  • tolerability
  • toxicity
Newsletter

Get great new content delivered to your inbox

Sign up
Related videos
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Leukemia, Lymphoma
CAR-T
ASCO 2019
Interview
2nd June 2019
More from Surbhi Sidana
QoL in patients undergoing CAR T-cell therapy versus transplantation
Varying VRd regimens in real-world patients
CAR T-cell therapy: how caregivers are affected
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Continue

Please enter your details if you would like to receive the latest hemonc news and updates

Sign up
Disease Channels
  • CLL
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • ALL
  • AML
  • Lymphoma
  • View all
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up
mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJHemOnc logo
The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy